In a groundbreaking phase 1 clinical trial at City of Hope®, one of the largest and most advanced cancer research and treatment centers in the U.S., researchers are exploring an innovative approach to treating rectal cancer. The trial seeks to transform rectal cancer—a disease notorious for its resistance to radiation—into a form that is much more responsive to radiation and chemotherapy. This new strategy, which uses the investigational drug papaverine, could pave the way for less invasive treatment options and dramatically improve the quality of life for patients.
A Pressing Need in Rectal Cancer Treatment
Rectal cancer, a subset of colorectal cancer, affects millions worldwide. Despite advancements in early diagnosis and treatment, many patients face challenging outcomes. While cancers such as prostate, lung, and cervical can often be managed with radiation therapy alone or in combination with chemotherapy, rectal cancer has proven stubbornly resistant to such treatments. Consequently, patients frequently require surgery—a procedure that, for many, means a permanent colostomy and a significant alteration in their quality of life.
For patients eligible for a “watch-and-wait” approach, where surgery might be deferred if the tumor responds well to non-invasive treatments, the promise of more effective radiation therapy is particularly enticing. By enhancing the sensitivity of rectal cancer tumors to radiation, physicians hope to maximize tumor destruction and reduce the need for radical surgical interventions.
The Role of Papaverine: Turning the Tide on Tumor Resistance
Central to this new trial is papaverine, an investigational drug traditionally used as a vasodilator. Recent preclinical studies have revealed that papaverine has an unexpected but promising role in oncology: it can sensitize tumor cells to radiation therapy. The mechanism appears to involve the inhibition of oxygen consumption by tumor cells. Since radiation therapy is more effective in the presence of oxygen, increasing the oxygen content in the tumor microenvironment can significantly enhance the treatment’s efficacy.
READ MORE: Epstein–Barr Virus Triggers Inflammatory Cell Death in Ulcerative Colitis, Study Finds
Dr. Terence Williams, M.D., Ph.D., Chair of the Department of Radiation Oncology at City of Hope and the principal investigator of the trial (NCT06834126), explains:
“Our research aims to block oxygen consumption in tumor cells using papaverine, thereby raising the oxygen levels within the tumor. With increased oxygen, radiation therapy becomes far more effective at destroying cancer cells. This could ultimately allow us to cure rectal cancer with radiation and chemotherapy, potentially sparing patients from the morbidity associated with surgery.”
Unveiling the DINOMITE Trial
The trial, dubbed the DINOMITE trial, represents a pioneering effort in rectal cancer treatment. It is designed to determine the side effect profile and establish the most effective dose of papaverine when administered alongside radiation therapy in patients with locally advanced rectal cancer—tumors that have spread to nearby tissues or lymph nodes but remain confined to the pelvis. The hope is that by enhancing the tumor’s sensitivity to radiation, the treatment will achieve maximal tumor destruction, reducing the need for surgery and thereby preserving patients’ quality of life.
In this trial, patients will receive papaverine in combination with standard radiation therapy, with careful monitoring of inflammatory markers, tumor response, and overall patient tolerance. Should the combination prove successful, it may set the stage for a paradigm shift in the treatment of rectal cancer, providing a non-invasive alternative to the current standard of care.
Bridging the Gap: From Bench to Bedside
City of Hope® is renowned for its “bench to bedside” approach to cancer research, quickly translating laboratory discoveries into clinical applications. This trial builds on a series of promising preclinical studies conducted in Dr. Williams’ laboratory, as well as prior work in related research groups. By leveraging advanced molecular techniques and rigorous animal models—using murine gamma-herpesvirus 68 (MHV-68) as a close relative of Epstein-Barr virus—the researchers have laid a robust foundation for this clinical investigation.
The concept behind this trial is simple yet revolutionary: if we can target the metabolic pathways that make rectal cancer resistant to radiation, we can fundamentally alter the course of the disease. Preclinical data has already demonstrated that inhibiting glycolysis—the process by which cells break down glucose for energy—with a compound like 2-deoxy-D-glucose (2-DG) can significantly reduce the inflammatory cell death (pyroptosis) in tumor-associated macrophages. This suggests that metabolic reprogramming of the tumor environment may be key to enhancing radiation efficacy.
Challenges and Future Directions
While the promise of papaverine is significant, the trial also faces several challenges. One major concern is ensuring that the inhibition of oxygen consumption is limited to tumor cells and does not adversely affect normal tissues. The precision of this intervention is critical, as systemic effects could lead to unintended consequences. Moreover, as with any novel therapeutic strategy, long-term safety and efficacy data will be essential.
Another challenge lies in the complex biology of rectal cancer itself. The tumor microenvironment is influenced by a myriad of factors, including immune responses, genetic mutations, and metabolic adaptations. Researchers must navigate these complexities to determine the optimal combination and dosage of papaverine with radiation therapy.
Looking ahead, if the DINOMITE trial demonstrates that papaverine effectively sensitizes rectal cancer to radiation, it could lead to further clinical trials that refine the treatment protocol. Future research may also explore combining papaverine with other therapeutic modalities, such as chemotherapy or targeted agents, to further enhance treatment outcomes. Additionally, this approach could be investigated in other types of cancer that exhibit radiation resistance, potentially broadening the impact of this discovery.
The Potential Impact on Patient Care
For patients with rectal cancer, the prospect of a non-surgical treatment option is particularly compelling. Surgery, while often necessary, carries significant risks and long-term lifestyle implications. A treatment that effectively harnesses radiation and chemotherapy to cure the disease would not only reduce the physical burden on patients but also improve their overall quality of life. Patients who might otherwise face a permanent colostomy could potentially retain their natural anatomy and avoid the psychological and physical challenges associated with major surgery.
The implications extend beyond individual patient care. A successful shift toward non-invasive treatments could reduce healthcare costs, minimize hospital stays, and lower the incidence of post-surgical complications. In a broader sense, such innovations represent the future of precision medicine—where treatments are tailored to the specific biological characteristics of a patient’s tumor, leading to more effective and less toxic therapies.
The Broader Landscape of Cancer Research
This trial is part of a larger trend in cancer research that seeks to exploit the unique metabolic vulnerabilities of tumors. In recent years, there has been growing interest in the role of metabolism in cancer progression and treatment resistance. By targeting the metabolic pathways that cancer cells rely on, researchers hope to develop therapies that are more selective and effective.
The research conducted at City of Hope® is a shining example of this approach. By focusing on glycolysis and the metabolic processes that fuel tumor growth and resistance, the team is charting a new course in oncology. If successful, this strategy could pave the way for a new class of treatments that transform how we approach not just rectal cancer, but potentially other cancers that share similar metabolic traits.
A Message of Hope in Colorectal Cancer Awareness
March is Colorectal Cancer Awareness Month—a time when millions are reminded of the challenges posed by this disease. Rectal cancer, in particular, constitutes about a third of all colorectal cancer cases. Innovations in treatment, such as the approach being tested in the DINOMITE trial, offer renewed hope for patients and their families. With more effective, less invasive treatments on the horizon, there is a real possibility of significantly improving survival rates and quality of life for those affected by rectal cancer.
Conclusion: A Step Toward Transformative Change
The DINOMITE trial at City of Hope® represents a bold step toward revolutionizing the treatment of rectal cancer. By harnessing the potential of papaverine to sensitize tumor cells to radiation, researchers are challenging long-held assumptions about the disease and opening the door to new, precision-based therapies. While the trial is still in its early stages, its implications are far-reaching—offering the potential to spare patients from the rigors of surgery and improve overall treatment outcomes.
As the trial progresses, the oncology community awaits further data with cautious optimism. Should these initial findings be confirmed, we may soon witness a paradigm shift in the way rectal cancer is treated—ushering in an era of therapies that are not only more effective but also significantly less invasive.
